Technical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis
Digestive Diseases and Sciences · 2023
DOI: 10.1007/s10620-023-08071-4 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Digestive Diseases and Sciences, 2023. Verfasst von Karen Smayra und 10 weiteren Autor:innen. Beteiligte Einrichtung: St George's University of London, London, SW17 0RE, UK. Hauptthemen laut MEDLINE: Digestive System Surgical Procedures, Liver Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The University of Queensland.
Abstract (Originalsprache)
BACKGROUND: Transjugular liver biopsy (TJLB) procedurally samples liver tissue through the internal jugular vein. It is indicated in the presence of coagulopathies and/or ascites. AIMS: This meta-analysis aimed to assess the safety and efficacy of TJLB in children. METHODS: A literature search of several databases was conducted from inception to August 2022. Eligible studies reported pediatric patients (< 18 years old) who underwent TJLB. The pooled proportion was analyzed using a random-effects model. This review was registered in PROSPERO (CRD42022354421). RESULTS: From 921 initial studies screened, eight met the eligibility criteria, with a total of 361 pediatric patients who underwent 374 TJLBs. All eight studies reported pooled rates of technical success at 99.1% (95% CI 0.982, 1.001; I2 = 0%) and histological adequacy of sampling at 97.5% (95% CI 0.954, 0.995; I2 = 27.66%). A total of 49 complications were reported across six studies, the most common being bleeding from the entry site (38.78%), fevers for less than 24 h (12.24%), red blood cells transfusion requirement (10.2%), supraventricular tachycardia (8.16%), and pain requiring analgesia (8.16%). CONCLUSION: Pediatric TJLB demonstrates high rates of technical success and adequate liver core biopsy samples, with a low rate of complications. These results suggest that TJLB is an effective method for diagnostic yield and postprocedural outcomes, especially in patients with preexisting coagulopathies and ascites where percutaneous liver biopsy is contraindicated. Additional studies evaluating larger groups of pediatric patients may provide further support for the use of TJLB in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- St George's University of London, London, SW17 0RE, UK.
- University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.
- Department of Medical Imaging, John Hunter Hospital, Newcastle, Australia.
- Faculty of Health, University of Newcastle, Newcastle, Australia.
- Cardiff and Vale University Health Board, Heath Park, Cardiff, CF14 4XW, UK.
- St George's University of London, London, SW17 0RE, UK. c.than@uq.edu.au.
Förderung
- The University of Queensland
Zitieren
APA
Smayra, K., Miangul, S., Yap, N., Shi, A., Abdulsalam, F., Adra, M., Nakanishi, H., Ball, J., Betts, T. A., Than, C. A., & Parthipun, A. (2023). Technical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-023-08071-4
Vancouver
Smayra K, Miangul S, Yap N, Shi A, Abdulsalam F, Adra M, et al. Technical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. 2023. doi:10.1007/s10620-023-08071-4
BibTeX
@article{Smayra2023,
author = {Smayra, Karen and Miangul, Shahid and Yap, Nathanael and Shi, Ao and Abdulsalam, Fatma and Adra, Maamoun and Nakanishi, Hayato and Ball, Jake and Betts, Tara A and Than, Christian A and Parthipun, Aneeta},
title = {Technical Success, Sample Adequacy, and Complications of Pediatric Transjugular Liver Biopsy: A Systematic Review and Meta-Analysis},
journal = {Digestive Diseases and Sciences},
year = {2023},
doi = {10.1007/s10620-023-08071-4}
}
EUVIMED